

![]() |
Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis |
|
Authors | ![]() | |
Published in | Rheumatology. 2016, vol. 55, no. 2, p. 230-236 | |
Abstract | To compare the effectiveness of biologics after rituximab (RTX) treatment in RA. | |
Keywords | Antirheumatic Agents/therapeutic use — Arthritis, Rheumatoid/drug therapy — Disease Progression — Europe — Female — Follow-Up Studies — Humans — Male — Middle Aged — Prospective Studies — Registries — Rituximab/therapeutic use — Time Factors — Treatment Outcome | |
Identifiers | PMID: 26316581 | |
Full text | ||
Structures | ||
Research group | Mécanisme de l'inflammation articulaire (44) | |
Citation (ISO format) | WALKER, Ulrich A et al. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. In: Rheumatology, 2016, vol. 55, n° 2, p. 230-236. doi: 10.1093/rheumatology/kev297 https://archive-ouverte.unige.ch/unige:86816 |